Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of ...

Vor Biopharma ( ($VOR) ) has provided an update. On December 15, 2025, Vor Bio entered into a securities purchase agreement for a $150 million ...

Press release 2 January 2026 On 31 July 2025, Lindab Group announced that an agreement had been reached to divest the profile business in Hungary. The divestment was completed on 31 December 2025, acc ...

Technia, in the Product Lifecycle Management division, announced today that it has acquired encad consulting's Dassault Systèmes customer agreements. Net sales for the acquired customer agreements are ...

The Honor Northwoods Flight is an organization that aims to send veterans to Washington D.C. in order to be able to see ...

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...

In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...

Vor Biopharma Inc. offers a high-risk, high-reward play on U.S. commercialization of telitacicept, a dual-target autoimmune drug approved in China. Complex warrant issuances and reverse stock split ...

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...

Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...